Ronald (Ronnie) Farquhar joined Morningside Biopharma Advisory as an entrepreneur-in-residence charged with the identification of innovative infection and immunity related investments. Approved products to which Ronnie has contributed include Miraviroc® and Ceftolozane/Tazobactam®. Prior to MBA, Ronnie was Senior Vice President, Discovery and Pharmaceutical Research at Cubist Pharmaceuticals for over six years. Prior to this, Ronnie served as head of Charles River Labs’ Preclinical Services, Massachusetts business and prior, as head of preclinical and discovery biology at ActivBiotics. Ronnie has also previously held senior positions at Millennium Pharmaceuticals, Pfizer Research, and Merck. He holds a D. Phil., Microbial Genetics from Oxford University and BSc, Microbiology from the University of Edinburgh.